Document Detail


Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension.
MedLine Citation:
PMID:  23194194     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: There are few clinical trials that provide evidence to support the hypothesis that combined therapies offer a favorable risk-benefit ratio in the reduction of cardiovascular mortality and morbidity. Combined therapies containing an angiotensin-converting enzyme inhibitor (ACEI) with a calcium channel blocker (CCB) is one of the recommended combinations in the reappraisal of the European Society of Hypertension.
AREAS COVERED: The authors have performed a systematic review of the available clinical evidence on the use of combined therapies containing an ACEI with a CCB versus other combinations in the management of arterial hypertension (HT) and in the reduction of cardiovascular morbidity/mortality, according to recommendations of The Cochrane Handbook for Systematic Reviews of Interventions. They identified 122 potentially relevant studies. Of these, 38 included combined therapies in one or both treatment arms. Overall, a total of 12 publications were retrieved from the search and provided data on the effects of the combined therapy with an ACEI and a CCB on cardiovascular mortality/morbidity in patients with HT. Clinical evidence corresponds to three double-blind clinical trials: ASCOT-BPLA, ACCOMPLISH and Syst-EUR.
EXPERT OPINION: The analysis demonstrates the superiority of the combined therapy with ACEI/CCB not only in the overall population included in the studies but also in subsets of patients with a high cardiovascular risk such as diabetes and chronic kidney disease.
Authors:
Josep Redón; Peter R A Trenkwalder; Vivencio Barrios
Related Documents :
18327624 - Cardiologist's knowledge and attitudes about obstructive sleep apnea: a survey study.
23050324 - A concise discussion of headache types, part 1.
16086614 - A trial of compliance therapy in outpatients with schizophrenia or schizoaffective diso...
23400444 - Effects of pharmacologic therapy on health-related quality of life in elderly patients ...
19210864 - Lack of correlation of the health assessment questionnaire disability index with lung p...
14754774 - Instability of symptoms in recurrent major depression: a prospective study.
Publication Detail:
Type:  Comparative Study; Journal Article; Review     Date:  2012-11-30
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  14     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-06-27     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  155-64     Citation Subset:  IM    
Affiliation:
Internal Medicine, Hospital Clínico de Valencia, University of Valencia, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain. josep.redon@uv.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use*
Antihypertensive Agents / therapeutic use
Calcium Channel Blockers / administration & dosage,  therapeutic use*
Cardiovascular Diseases / etiology,  prevention & control
Clinical Trials as Topic
Drug Therapy, Combination
Humans
Hypertension / drug therapy*,  physiopathology
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current level of glycaemic control and its associated factors in patients with type 2 diabetes acros...
Next Document:  Virtual Histology Analysis of Carotid Atherosclerotic Plaque: Plaque Composition at the Minimum Lume...